| 摘要 |
Tamoxifen is the drug of choice in the initial hormonal treatment for both premenopausal and postmenopausal women with ER-positive breast car-cinoma. Generally, the drug is well tolerated, although case reports have documented ocular toxicity in patients receiving very-high-dose tamoxifen >180 mg/d). The ocular side effects include corneal changes, optic neuritis, retinopathy, and macular edema. As the currently recommended dose of the drug is 20 mg per day, we attempted to determined the prevalence of ocular toxicity in patients treated with such a low daily dose of tamoxifen. This study included 75 breast cancer patients who had been treated with tamoxifen for variable periods of duration after surgical intervention and who had undergone ocular examinations before any visual symptoms had appeared. The mean duration of tamoxifen treatment was 16.2 months (range 2-49 months). The mean cumulative dose of the 75 patients was 9.7+
6.6 gm (range 1.2-31.8 gm). No tamoxifen-related ocular toxicity was noted the
in our study. Although our data showed no tamoxifen ocular toxicity in asymptomatic patients during the course of current tamoxifen therapy, ocular safety of higher cumulative dosages recommended by conventional Thus, therapy is still unknown. all physicians should still be aware of the potential of ocular toxicity associated with tamoxifen and encourage baseline ophthalmologic evaluations and close monitoring of any ocular complaints that might arise during therapy. If any ophthalmic complica-tions should occur, tamoxifen should be discontinued immediately. It is important to keep in mind that even low dose tamoxifen can induce ocular toxicity. The potential ocular toxicity of tamoxifen, even at low doses, can by no means be overlooked. |
